Médicament Québec Funds Four Innovative Vaccine Technology Initiatives
September 9, 2025 – News from Médicament Québec
Montréal, QC, September 9, 2025 – Médicament Québec is proud to announce an investment of $5.37 million to support four initiatives through its Innovations in Vaccine Technologies program.
Funded by the Government of Québec, this program is designed to stimulate and support large-scale, collaborative academic initiatives that strengthen Québec’s vaccine technology capabilities and address critical needs within the provincial vaccine ecosystem.
The program focuses on developing platforms, tools, and sustainable practices that deliver tangible benefits to the Québec public. Beyond scientific innovation, the goal is to build infrastructures and networks that accelerate vaccine discoveries and foster partnerships between academic and industry stakeholders.
The four funded initiatives:
- Dr. Gregory De Crescenzo – Department of Chemical Engineering, Polytechnique Montréal
Development of a new CHO platform for manufacturing intranasal influenza vaccines – $1.43 M - Dr. Jérôme Estaquier – Department of Microbiology, Infectiology & Immunology, Université Laval
Preclinical tools and services to decode B- and T-cell repertoires induced by immune responses in non-human primates – $0.94 M - Dr. Bruno Gaillet – Department of Chemical Engineering, Université Laval
Lipid nanoparticle platform with active endosomal escape system for mRNA vaccines – $1.5 M - Dr. Ciriaco Piccirillo – Department of Microbiology & Immunology, Research Institute of the McGill University Health Centre (RI-MUHC)
Creation of a Québec human immunology network to support the provincial vaccine ecosystem – $1.5 M
Each initiative involves collaboration among leading university researchers and partners from industry and the broader life sciences ecosystem, ensuring that projects address concrete needs and benefit from strong alignment between research and application.
“The initiatives we are funding this year perfectly reflect our vision: to build bridges between academic research and the concrete needs of industry. Our aim is to design capacities, resources, and ways of working that will allow the entire ecosystem to grow and innovate more effectively in developing new vaccines,” said Arianne Trudeau, Project Director, Médicament Québec.
For more information about each initiative and to learn about the expected outcomes, visit this page.
Stay tuned: additional initiatives funded under the Innovations in Vaccine Technologies program will be announced soon.
—30—
Media Contact
Arianne Trudeau
Project Director
Médicament Québec
arianne.trudeau@umontreal.ca
About Médicament Québec
Médicament Québec (MQ), an initiative funded by the Government of Québec, brings together research and teaching institutions as well as companies around a shared mission. Its goal is to strengthen Québec’s and Canada’s autonomy and dynamism in bioinnovation and biomanufacturing. MQ supports large-scale, collaborative academic research initiatives that reinforce local supply chains in the field of medicines.
Comments are closed.